Impaired PGC-1alpha function in muscle in Huntington's disease. - Wikidata - wikimedia - TriplyDB

Impaired PGC-1alpha function in muscle in Huntington's disease.

Impaired PGC-1alpha function in muscle in Huntington's disease.

http://www.wikidata.org/entity/Q37323316

about

The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease Potential Role of Omega-3 Fatty Acids on the Myogenic Program of Satellite Cells The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review Mouse models of polyglutamine diseases: review and data table. Part I PGC-1α, mitochondrial dysfunction, and Huntington's disease Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Transcriptional coregulators: emerging roles of SRC family of coactivators in disease pathology Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases Shaping the role of mitochondria in the pathogenesis of Huntington's disease Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis Mitochondrial dysfunction in neurodegenerative diseases Metabolism in HD: still a relevant mechanism?Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.Effects of creatine and β-guanidinopropionic acid and alterations in creatine transporter and creatine kinases expression in acute seizure and chronic epilepsy models.Parvalbumin deficiency and GABAergic dysfunction in mice lacking PGC-1alpha Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders.Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?Skeletal muscle pathology in Huntington's disease PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons.Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment.Localization of sequence variations in PGC-1α influence their modifying effect in Huntington disease.Exercise increases mitochondrial PGC-1alpha content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis.Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease.HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease.Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1α) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease

P2860

Q22306292-397ADAD8-9C84-4516-915A-6888B34772E3 Q26765367-4ADDEBEE-8512-4653-8637-A447ACB7E3A0 Q26822632-AAD20DF4-2038-4AA5-A446-2794943EBDC8 Q26853025-10FCB4C4-54EB-4A4A-86F3-0324FBDE88B0 Q27001671-5F3028E1-BEE9-48E1-9398-8E9251F06E5D Q27005950-E4F7A4B3-EF90-4037-B8C6-8FC42DFFB2D1 Q27030886-8CAA4E35-1FF5-487A-8429-6F5F2941F0F2 Q28079898-4D0E7320-1192-4570-B84C-3FABFC845B15 Q28384036-E68C5EAF-0B56-4E67-8DDC-684C38118204 Q28386202-B7C81646-36F3-4ACC-878F-BC6754E48F20 Q28387647-0561502E-F4D3-4B73-AB28-7F5F813B420A Q28394301-D0EB8CE8-96E2-4DAF-BCA6-5FF8C380F8BC Q30498491-C40A0F56-2C5A-404E-99DF-D1F5E1F89340 Q30574513-A2A27CBF-B9CE-4F80-A339-373239641209 Q30583566-DFEA0936-599C-4B59-BB87-B10832932A6A Q33517121-DDEE1C8A-0278-435D-8CFC-71359FBF950C Q33729818-6C782FC2-67F7-4FD7-9C50-4250E75567E8 Q33922914-44AACC6D-4C53-439D-B1E8-8358C84FD50E Q34042260-174FCC86-751C-48E4-80B8-62FB04A61609 Q34043950-0676C5ED-24DF-4834-A922-3DDCF808BDDF Q34163054-14A5A00D-67D4-4D0B-AB4F-4B94E2C1AE5C Q34215149-F7DEF32E-F1B0-4E5A-B6C5-E29086F747E6 Q34284039-5D9C1C34-C3F9-4144-A53B-78E454B9347E Q34292092-7C640530-F5F6-425D-AACB-675DC8BED314 Q34383492-C30CFADF-8F9F-439D-A14A-30CACE0D9ED9 Q34391101-41A6778E-79AA-44EC-A1E6-D750E1C81093 Q34409630-ABB5E905-BE65-4B26-8C05-CFEB8BC44E1B Q34443537-D8B9C953-A008-49D7-BCC3-4FB6EE25FE6E Q34498391-CC70F17C-3114-4BCC-9F56-F65615A96AF6 Q34695923-A63C6A38-3853-479E-8526-1A5107814F9F Q34743269-F8F1A16C-82D7-4F30-82E6-D6EE05A86FCC Q34838143-645D6E31-C63D-4800-B172-E3990BDA65C5 Q34926539-51A916BA-7508-4D51-BD57-59E9CFEA7E37 Q34944325-0C7E3DF3-B46B-47B6-AC35-08483B7E6A9C Q34994779-81F48F26-7983-47D5-8AEC-383194E0C9BE Q35052819-64A241D6-5FDA-44D3-AD4B-163213602E1B Q35086831-385FA7F7-8C48-4315-A0C4-E58D20C448F6 Q35130191-4055FA43-78F2-4262-BF37-90EC1749C783 Q35166545-4A97F1C3-E9A4-447C-B87D-1458B8A7FAED Q35268092-00A12BC1-193F-4699-A368-20D2909533D7

P2860

Impaired PGC-1alpha function in muscle in Huntington's disease.

http://www.wikidata.org/entity/Q37323316

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impaired PGC-1alpha function in muscle in Huntington's disease.

@en

Impaired PGC-1alpha function in muscle in Huntington's disease.

@nl

type

label

Impaired PGC-1alpha function in muscle in Huntington's disease.

@en

Impaired PGC-1alpha function in muscle in Huntington's disease.

@nl

prefLabel

Impaired PGC-1alpha function in muscle in Huntington's disease.

@en

Impaired PGC-1alpha function in muscle in Huntington's disease.

@nl

P1433

Q37323316-0B5A62D4-FCC6-4607-8D1B-98D10340BBB0

P1476

Q37323316-58C92A50-85C7-48A8-842E-8BBF2CB5DECD

P2093

Q37323316-052B78F0-736C-4A42-B99E-DCDC3D0A1214

Q37323316-1A06B7FA-2C5F-49F9-91AF-CC4C6B53B966

Q37323316-527BEB18-9CDD-4724-890F-E90241A4EDA9

Q37323316-A276FCEC-4780-4F7E-9F49-E6DB4EACC82C

Q37323316-BB3DFD0E-0544-423E-B74A-831F25649893

Q37323316-BC5EFD81-D710-4FCC-AFD5-5D943A8E0B17

Q37323316-C47C44EA-A29C-453E-ADCB-3F5A96595E12

Q37323316-C9D3A2A7-A02C-4FBF-97ED-B24D121FC2EB

Q37323316-EAC267AC-21C8-4896-82C9-F2B36B3E38C1

P2860

Q37323316-01223A5E-38F5-4DA9-8C40-3C8A84A9505C

Q37323316-04658E92-7009-46B9-B949-C4EC8F2B42B4

Q37323316-103DDE02-5933-45A6-8E91-378B6A63683B

Q37323316-13EEA59E-938B-41D2-8C09-738091095DA9

Q37323316-15598A26-1EEC-43FB-9C0F-B3A9BE8A2DAA

Q37323316-1709183D-FDC6-47CD-AD64-94459786A1D3

Q37323316-17B91871-A533-4679-849C-D88A1BF04B04

Q37323316-1BC36D9B-1C95-4EF0-8248-C5D7AB3F2F3D

Q37323316-1F4E5ADE-082B-4C58-985B-349F40252C5D

Q37323316-203FEF9C-F664-4F50-9755-00A3321C357A

P304

Q37323316-E135A43B-DE6C-4688-85FC-4A0A9A79A079

P31

Q37323316-AC21E1E8-8964-4678-84E6-003719C66DEB

P356

Q37323316-5F140CCE-275E-465F-AB97-BA104772E782

P433

Q37323316-32F2D6CE-E866-4D15-B6B9-F9008EB280A4

P478

Q37323316-17C4ABDE-5E06-4B84-B36C-3576F1E23785

P50

Q37323316-1F0EA2A8-71AB-4784-85B9-5D6150C4277B

Q37323316-3AF54E91-97A1-457A-A67B-1DFBC5989836

Q37323316-3EDBDB74-B32C-4976-8BBA-A3711DB5E8FD

Q37323316-DEC452EB-31FC-4BCE-A3FE-028BAD218878

P577

Q37323316-B5E39EF6-8DBC-40C5-BD6B-EB47A681D170

P5875

Q37323316-35BCCD75-DA31-4CC9-8013-557B34551717

P698

Q37323316-A2F90454-22B9-4DFC-934D-A843188D8CAC

P921

Q37323316-CFE7B0D3-EDEC-40A6-B6BD-89C8DE72CF43

P932

Q37323316-E6B03227-06BC-4190-AE4A-42832939EA8F

P356

P1433

Human Molecular Genetics

P1476

Impaired PGC-1alpha function in muscle in Huntington's disease

@en

P2093

Andrea Ciammola

http://www.w3.org/2001/XMLSchema#string

Jenny Sassone

http://www.w3.org/2001/XMLSchema#string

Lichuan Yang

http://www.w3.org/2001/XMLSchema#string

M Flint Beal

http://www.w3.org/2001/XMLSchema#string

Mahmoud Kiaei

http://www.w3.org/2001/XMLSchema#string

Noel Calingasan

http://www.w3.org/2001/XMLSchema#string

Peter Adhihetty

http://www.w3.org/2001/XMLSchema#string

Shubha Shukla

http://www.w3.org/2001/XMLSchema#string

Thomas Hennessy

http://www.w3.org/2001/XMLSchema#string

P2860

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription

Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator

The regulation of AMP-activated protein kinase by phosphorylation

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation.

Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle

PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis

A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis

Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1

Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease

P304

3048-3065

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDP243

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Rajnish Kumar Chaturvedi

Ferdinando Squitieri

Milena Cannella

Anatoly Starkov

P577

2009-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24445035

http://www.w3.org/2001/XMLSchema#string

P698

19460884

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

2733807

http://www.w3.org/2001/XMLSchema#string